Pomerantz LLP has filed a class action lawsuit against Doximity, Inc., alleging securities fraud and unlawful business practices by the company and some of its executives. The lawsuit follows a series of significant stock price declines triggered by Doximity's cautious outlook on ad spending, lowered revenue guidance, and missed revenue targets between late 2025 and mid-2026. Investors who suffered losses during this period are encouraged to join the lawsuit by November 16, 2026. This legal action highlights concerns over Doximity's financial management and future growth prospects.
Regarding the class action lawsuit involving Doximity, Inc., here is Pluang's snapshot of the health sector as of Oct 14, 2026 03:41 WIB: Out of 128 priced US health stocks tradable on Pluang, 29 rose and 99 fell today. Notable movers include BioNTech SE - ADR (BNTX) at USD 89.78 with a 1-day change of -6.32% and a typical hold time on Pluang of 60 days, Citius Pharmaceuticals Inc (CTXR) at USD 0.47 down 5.60% with a 17-day typical hold time and 100% buy order activity, and Johnson & Johnson (JNJ) at USD 248.96 down 5.60% with a 129-day typical hold time and 57% buy order activity.
ZenaTech announced a 27.1% organic revenue growth in its Drone as a Service (DaaS) operations in 2026, driven by integrating AI and drones into surveying and inspection workflows. The company expects Q3 2026 revenues between C$13.4 million and C$14.8...
Nvidia CEO Jensen Huang has reaffirmed his long-standing forecast that global spending on AI infrastructure will surge to between $3 trillion and $4 trillion by 2030. This projection highlights the massive growth potential in the AI sector, driven by...
Targa Resources Corp. announced a quarterly cash dividend of $1.25 per common share for Q3 2026, payable on November 17, 2026, to shareholders of record as of October 30, 2026. The company will release its Q3 2026 financial results before market open...
On October 13, 2026, several stocks including Adlai Nortye, Omada Health, Syndax Pharmaceuticals, Six Flags, and Immunic saw significant declines. Syndax dropped 15.7% after its Phase 2 trial for a lung disease drug failed, leading to halted developm...
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
